SNORD114-1: SNORD114-1 is a box C/D small nucleolar RNA (snoRNA) that has been shown to play a role in cell proliferation and cell cycle progression in various types of leukemia, including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) [PMC4427830] [PMC6789762] [PMC8975097]. It has been reported that SNORD114-1 regulates the cell cycle transition mediated by the Rb/p16 pathway in AML [PMC8975097]. SNORD114-1 variants have been found to cause cell cycle arrest at G0/G1 and inhibit cell growth [PMC9098889]. Additionally, sdRNAs produced from SNORD114-1 have been found to be positively correlated with endothelial cell abundance in various cancer types, suggesting a role in tumor vascularization [PMC9149963]. Suppression of SNORD114-1 has been shown to increase apoptosis through a p53-dependent manner in non-small-cell lung cancer [PMC5390076]. Overexpression of SNORD114-1 has been found to promote cell growth through affecting the Rb/p16 pathway in acute leukemia [PMC6686521] [PMC5796982]. Furthermore, downregulation of SNORD114-1 has been observed in glioblastoma multiforme (GBM) tumor tissue compared with normal brain tissue, suggesting its potential role as a tumor suppressor [PMC7746944]. In bladder cancer, SNORD114-1 has been identified as a harmful factor for patient survival [PMC7350589]. Overall, these findings highlight the importance of SNORD114-1 in cancer biology and suggest its potential as a therapeutic target for leukemia and other cancers.